Adaptive Biotechnologies Corp ADPT:NASDAQ

Last Price$12.32NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$10.12 (78)
Ask (Size)$13.20 (10)
Day Low / HighN/A - N/A
Volume966.1 K
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Adaptive Biotechnologies Corp ( NASDAQ )

Price: $12.32
Change: +0.20 (1.65%)
Volume: 966.1 K
4:00PM ET 8/12/2022
 
 

BridgeBio Pharma Inc ( NASDAQ )

Price: $11.60
Change: +0.72 (6.62%)
Volume: 1.9 M
4:00PM ET 8/12/2022
 
 

Immunitybio Inc ( NASDAQ )

Price: $4.52
Change: +0.10 (2.26%)
Volume: 671.8 K
4:00PM ET 8/12/2022
 
 

Xencor Inc ( NASDAQ )

Price: $30.47
Change: +1.81 (6.32%)
Volume: 279.4 K
4:00PM ET 8/12/2022
 
 

Veracyte Inc ( NASDAQ )

Price: $26.05
Change: +0.56 (2.20%)
Volume: 620.7 K
4:00PM ET 8/12/2022
 

Read more news Recent News

--BTIG Adjusts Price Target for Adaptive Biotechnologies to $17 From $25, Maintains Buy Rating
3:12PM ET 8/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Posts Q2 Revenue $43.7M
4:07PM ET 8/03/2022 MT Newswires

...

Adaptive Biotechnologies Launches New T-Cell Test for Lyme Disease
7:58AM ET 6/15/2022 MT Newswires

Adaptive Biotechnologies (ADPT) said Wednesday it launched its new T-cell test for the early detection of Lyme disease in adult patients who show signs and...

Piper Sandler Starts Adaptive Biotechnologies at Neutral With $7.50 Price Target
6:00AM ET 6/03/2022 MT Newswires

Adaptive Biotechnologies (ADPT) has an average rating of outperform and price targets ranging from $7.50 to $25, according to analysts polled by Capital...

Company Profile

Business DescriptionAdaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA. View company web site for more details
Address1165 Eastlake Avenue East
Seattle, Washington 98109
Phone+1.206.659.0067
Number of Employees346
Recent SEC Filing08/05/20224
Chairman & Chief Executive OfficerChad Robins
PresidentJulie Rubinstein
Chief Operating & Technical OfficerR. Mark Adams
Chief Financial OfficerTycho W. Peterson

Company Highlights

Price Open$12.23
Previous Close$12.12
52 Week Range$5.96 - 40.00
Market Capitalization$1.8 B
Shares Outstanding142.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.64
Beta vs. S&P 500N/A
Revenue$55.7 M
Net Profit Margin-145.37%
Return on Equity-39.90%

Analyst Ratings as of 06/01/2022

Buy
5
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset